Tumor organoid-originated biomarkers predict immune response to PD-1 blockade
- 2 September 2021
- journal article
- editorial
- Published by Elsevier BV in Cancer Cell
- Vol. 39 (9), 1187-1189
- https://doi.org/10.1016/j.ccell.2021.08.003
Abstract
No abstract availableFunding Information
- Icahn School of Medicine at Mount Sinai
This publication has 10 references indexed in Scilit:
- An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancerNature Medicine, 2021
- Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancerScience, 2020
- The Challenges of Tumor Mutational Burden as an Immunotherapy BiomarkerCancer Cell, 2020
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of EvidenceCancers, 2020
- Clonal replacement of tumor-specific T cells following PD-1 blockadeNature Medicine, 2019
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanomaNature Medicine, 2019
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImmunity, 2019
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyScience, 2018
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockadeNature Medicine, 2018
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014